Role of Ga-68 Prostate Specific Membrane Antigen PET/CT scan in brain tumor patients for detection of recurrence
Phase 4
- Conditions
- Health Condition 1: C719- Malignant neoplasm of brain, unspecified
- Registration Number
- CTRI/2024/02/062919
- Lead Sponsor
- AIIMS, Bhubaneswar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients with age more than18 years.
Patients having past history of histologically proven glioma.
Patients who have undergone prior treatment with tumor resection and/or radiation therapy and/or chemotherapy.
Clinically suspected cases of recurrence.
Patient should be willing to and able to give written informed consent
Exclusion Criteria
Pregnant lady.
Breastfeeding mother.
Patients who will deny to give consent.
Any brain primary other than high grade glioma
Patient diagnosed with other primary malignancy
Patient with life threating neurological emergency
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary objective <br/ ><br>Detection of sensitivity and specificity of 68Ga PSMA-11 PET-CT to diagnose disease recurrence in gliomas <br/ ><br>Timepoint: 3 months
- Secondary Outcome Measures
Name Time Method Secondary objectives <br/ ><br>1. Comparison of tumor SUVmax between 68Ga-PSMA and 18F-FDG PET-CT images <br/ ><br>2. Comparison of sensitivity and specificity of Ga-68 PSMA-11 PET-CT with that of CEMRI in diagnosing disease recurrence in gliomas <br/ ><br>3. Correlation between WHO tumor grade in histology and SUVmax of the recurrent lesion on 68Ga- PSMA PET-CT scan <br/ ><br>4. Correlation between PSMA expression in histopathology specimen (using IHC) and SUVmax of recurrent lesion on 68Ga- PSMA PET-CT scan.Timepoint: 3 months